메뉴 건너뛰기




Volumn 12, Issue , 2011, Pages

Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches

Author keywords

[No Author keywords available]

Indexed keywords

FORMOTEROL; INDACATEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; 5 (2 (5,6 DIETHYLINDAN 2 YLAMINO) 1 HYDROXYETHYL) 8 HYDROXY 1H QUINOLIN 2 ONE; 5-(2-(5,6-DIETHYLINDAN-2-YLAMINO)-1-HYDROXYETHYL)-8-HYDROXY-1H-QUINOLIN-2-ONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; INDAN DERIVATIVE; QUINOLONE DERIVATIVE;

EID: 79955098782     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-12-54     Document Type: Article
Times cited : (39)

References (23)
  • 1
    • 77953707790 scopus 로고    scopus 로고
    • Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD
    • 10.1136/thx.2009.125435, 20522841
    • Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010, 65:473-479. 10.1136/thx.2009.125435, 20522841.
    • (2010) Thorax , vol.65 , pp. 473-479
    • Dahl, R.1    Chung, K.F.2    Buhl, R.3    Magnussen, H.4    Nonikov, V.5    Jack, D.6    Bleasdale, P.7    Owen, R.8    Higgins, M.9    Kramer, B.10
  • 3
    • 77951221549 scopus 로고    scopus 로고
    • Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study
    • 10.1186/1471-2466-10-11, 2848004, 20211002
    • Feldman G, Siler T, Prasad N, Jack D, Piggott S, Owen R, Higgins M, Kramer B. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010, 10:11. 10.1186/1471-2466-10-11, 2848004, 20211002.
    • (2010) BMC Pulm Med , vol.10 , pp. 11
    • Feldman, G.1    Siler, T.2    Prasad, N.3    Jack, D.4    Piggott, S.5    Owen, R.6    Higgins, M.7    Kramer, B.8
  • 4
    • 79953026850 scopus 로고    scopus 로고
    • Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison
    • Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B. Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2010, 37:273-279.
    • (2010) Eur Respir J , vol.37 , pp. 273-279
    • Kornmann, O.1    Dahl, R.2    Centanni, S.3    Dogra, A.4    Owen, R.5    Lassen, C.6    Kramer, B.7
  • 5
    • 77950340063 scopus 로고    scopus 로고
    • Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design
    • 10.1016/j.pupt.2010.01.003, 20080201
    • Barnes PJ, Pocock SJ, Magnussen H, Iqbal A, Kramer B, Higgins M, Lawrence D. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther 2010, 23:165-171. 10.1016/j.pupt.2010.01.003, 20080201.
    • (2010) Pulm Pharmacol Ther , vol.23 , pp. 165-171
    • Barnes, P.J.1    Pocock, S.J.2    Magnussen, H.3    Iqbal, A.4    Kramer, B.5    Higgins, M.6    Lawrence, D.7
  • 6
    • 77954102187 scopus 로고    scopus 로고
    • Once-daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD)
    • Rennard SI, Chapman KR, Luthra A, Swales J, Lassen C, Owen R, Kramer B. Once-daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD). Chest 2009, 136:4S.
    • (2009) Chest , vol.136
    • Rennard, S.I.1    Chapman, K.R.2    Luthra, A.3    Swales, J.4    Lassen, C.5    Owen, R.6    Kramer, B.7
  • 8
    • 0036014549 scopus 로고    scopus 로고
    • Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial
    • 10.1183/09031936.02.00240902, 12030736
    • Aalbers R, Ayres J, Backer V, Decramer M, Lier PA, Magyar P, Malolepszy J, Ruffin R, Sybrecht GW. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 2002, 19:936-943. 10.1183/09031936.02.00240902, 12030736.
    • (2002) Eur Respir J , vol.19 , pp. 936-943
    • Aalbers, R.1    Ayres, J.2    Backer, V.3    Decramer, M.4    Lier, P.A.5    Magyar, P.6    Malolepszy, J.7    Ruffin, R.8    Sybrecht, G.W.9
  • 9
    • 0029031264 scopus 로고
    • Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study
    • 10.1016/0954-6111(95)90008-X, 7638371
    • Cazzola M, Matera MG, Santangelo G, Vinciguerra A, Rossi F, D'Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995, 89:357-362. 10.1016/0954-6111(95)90008-X, 7638371.
    • (1995) Respir Med , vol.89 , pp. 357-362
    • Cazzola, M.1    Matera, M.G.2    Santangelo, G.3    Vinciguerra, A.4    Rossi, F.5    D'Amato, G.6
  • 10
    • 0028814552 scopus 로고
    • Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease
    • 10.1136/thx.50.1.62, 473711, 7886652
    • Ikeda A, Nishimura K, Koyama H, Izumi T. Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Thorax 1995, 50:62-66. 10.1136/thx.50.1.62, 473711, 7886652.
    • (1995) Thorax , vol.50 , pp. 62-66
    • Ikeda, A.1    Nishimura, K.2    Koyama, H.3    Izumi, T.4
  • 12
    • 43549104866 scopus 로고    scopus 로고
    • Systemic and bronchodilator effects of inhaled rac-formoterol in subjects with chronic obstructive pulmonary disease: a dose-response study
    • 10.1111/j.1365-2125.2007.03081.x, 2485218, 18394012
    • Whale CI, Sovani MP, Mortimer KJ, Harrison TW, Tattersfield AE. Systemic and bronchodilator effects of inhaled rac-formoterol in subjects with chronic obstructive pulmonary disease: a dose-response study. Br J Clin Pharmacol 2008, 65:841-847. 10.1111/j.1365-2125.2007.03081.x, 2485218, 18394012.
    • (2008) Br J Clin Pharmacol , vol.65 , pp. 841-847
    • Whale, C.I.1    Sovani, M.P.2    Mortimer, K.J.3    Harrison, T.W.4    Tattersfield, A.E.5
  • 13
    • 64249171524 scopus 로고    scopus 로고
    • 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol
    • 10.1185/03007990802675096, 19192991
    • Bauwens O, Ninane V, Van de Maele B, Firth R, Dong F, Owen R, Higgins M. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr Med Res Opin 2009, 25:463-470. 10.1185/03007990802675096, 19192991.
    • (2009) Curr Med Res Opin , vol.25 , pp. 463-470
    • Bauwens, O.1    Ninane, V.2    Van de Maele, B.3    Firth, R.4    Dong, F.5    Owen, R.6    Higgins, M.7
  • 18
    • 0003736032 scopus 로고    scopus 로고
    • Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease
    • GOLD
    • GOLD Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2007, GOLD.
    • (2007)
  • 19
    • 0003736032 scopus 로고    scopus 로고
    • Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease
    • GOLD
    • GOLD Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2009, GOLD.
    • (2009)
  • 20
    • 22744439763 scopus 로고    scopus 로고
    • Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease
    • 10.1517/13543784.14.7.775, 16022567
    • Cazzola M, Matera MG, Lotvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005, 14:775-783. 10.1517/13543784.14.7.775, 16022567.
    • (2005) Expert Opin Investig Drugs , vol.14 , pp. 775-783
    • Cazzola, M.1    Matera, M.G.2    Lotvall, J.3
  • 21
    • 28244497329 scopus 로고    scopus 로고
    • Measuring the effects of COPD on the patient
    • Jones P, Lareau S, Mahler DA. Measuring the effects of COPD on the patient. Respir Med 2005, 99:S11-S18.
    • (2005) Respir Med , vol.99
    • Jones, P.1    Lareau, S.2    Mahler, D.A.3
  • 22
    • 0021256105 scopus 로고
    • The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes
    • 10.1378/chest.85.6.751, 6723384
    • Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984, 85:751-758. 10.1378/chest.85.6.751, 6723384.
    • (1984) Chest , vol.85 , pp. 751-758
    • Mahler, D.A.1    Weinberg, D.H.2    Wells, C.K.3    Feinstein, A.R.4
  • 23
    • 84857983364 scopus 로고    scopus 로고
    • Correlating changes in lung function with patient reported outcomes in COPD (abstract)
    • Jones PW, Donohue J, Nedelman J, Pinault G, Pascoe S. Correlating changes in lung function with patient reported outcomes in COPD (abstract). Thorax 2010, 65:A141.
    • (2010) Thorax , vol.65
    • Jones, P.W.1    Donohue, J.2    Nedelman, J.3    Pinault, G.4    Pascoe, S.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.